Neuronetics Inc (STIM) Stock Price, Quote & News

Company Profile

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific ar...

Industry: Medical Devices

Sector: Healthcare

Phone: 877 600 7555

Fax: 610 640 4206

Website: neurostar.com

Address:

3222 Phoenixville Pike, Malvern, United States

jacckkmm Sep. 18 at 1:17 PM

$STIM looking for a solid move today going into weekend…

0 · Reply

jacckkmm Sep. 17 at 7:58 PM

$STIM get to $3 :)

0 · Reply

Oscar_66 Sep. 17 at 5:06 PM

$STIM Looky looky!

0 · Reply

StellaLunaSun Sep. 17 at 2:29 PM

$STIM this is about to geht crazy BUT watch BEAM GLOBAL today: https://www.marketscreener.com/news/beam-global-and-masdar-city-free-zone-signs-memorandum-of-understanding-to-explore-sustainable-energ-ce785bd3dc89f424

0 · Reply

LurkerLongtime Sep. 15 at 9:27 PM

$ATAI if you want some risk, take a portion to $OPTH .. Another pick and shovel play -> $STIM .. Unrelated, but I'm also loading $TLRY .. It was a ride here. Whether a good one, IDK. But a ride nonetheless. Stay diligent, Atai friends.

0 · Reply

Ren_Stimpy Sep. 14 at 3:47 PM

$STIM sold half my share holdings for $3.20! Locked in some decent profits.

0 · Reply

MingChoo Sep. 13 at 2:03 PM

$STIM Upside potential

0 · Reply

Ren_Stimpy Sep. 11 at 7:55 PM

$STIM Sadly we probably won’t get any good PR till earnings. Short sellers will probably try and keep stock price low as they cover. Don’t see any big price movements in the near future.

1 · Reply

sam92 Sep. 11 at 3:14 PM

$STIM Consensus Price Target Increase: Consensus analyst price targets were recently revised upward to $6.00 (up from $4.50–$5.25), implying significant upside potential based on expected benefits from its Greenbrook TMS platform integration.

1 · Reply

Ren_Stimpy Sep. 11 at 11:51 AM

$STIM Finally got our analysis update!! Was starting to think it was never going to come..

0 · Reply

Neuronetics initiated with a Buy at B. Riley

2026-09-08T17:00:23.000Z - 13 days ago

Neuronetics management to meet virtually with BTIG

Sep 8, 2026, 8:32 AM EDT - 13 days ago

NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System

Aug 11, 2026, 8:30 AM EDT - 5 weeks ago

Neuronetics Earnings Call Transcript: Q2 2026

Aug 11, 2026, 8:30 AM EDT - 5 weeks ago

Neuronetics Slides: Q2 2026

Aug 11, 2026, 8:30 AM EDT - 5 weeks ago

Neuronetics Earnings release: Q2 2026

Aug 11, 2026, 8:30 AM EDT - 5 weeks ago

Neuronetics Quarterly report: Q2 2026

2026-08-11T11:55:20.000Z - 5 weeks ago

Neuronetics reports Q2 EPS (5c), consensus (12c)

Aug 3, 2026, 8:00 AM EDT - 7 weeks ago

Neuronetics and Jorey Chernett Announce Shared Vision

Jul 31, 2026, 5:00 PM EDT - 7 weeks ago

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 28, 2026, 8:32 AM EDT - 7 weeks ago

Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland

Jul 28, 2026, 8:30 AM EDT - 7 weeks ago

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call

2026-07-20T20:15:49.000Z - 2 months ago

Neuronetics appoints Nir Naor as CFO, CLO Andrew Macan to step down

AXGN

Jul 20, 2026, 4:05 PM EDT - 2 months ago

Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes

2026-07-20T10:11:07.000Z - 2 months ago

Neuronetics initiated with a Buy at BTIG

Jul 6, 2026, 8:30 AM EDT - 2 months ago

Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026

Jun 2, 2026, 4:30 PM EDT - 3 months ago

Neuronetics Appoints Robert Greene as Senior Vice President Sales

Jun 2, 2026, 8:32 AM EDT - 3 months ago

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

May 28, 2026, 8:00 AM EDT - 3 months ago

Neuronetics Transcript: AGM 2026

May 14, 2026, 8:32 AM EDT - 4 months ago

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

2026-05-05T12:37:49.000Z - 4 months ago

Neuronetics reports Q1 EPS (16c), consensus (17c)

2026-05-05T12:33:13.000Z - 4 months ago

Neuronetics backs FY26 revenue view $160M-$166M, consensus $162.47M

May 5, 2026, 8:30 AM EDT - 4 months ago

Neuronetics Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 4 months ago

Neuronetics Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 4 months ago

Neuronetics Slides: Q1 2026

May 5, 2026, 8:30 AM EDT - 4 months ago

Neuronetics Quarterly report: Q1 2026

May 5, 2026, 7:50 AM EDT - 4 months ago

Neuronetics Reports First Quarter 2026 Financial and Operating Results

Apr 21, 2026, 8:30 AM EDT - 5 months ago

Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call

Apr 13, 2026, 8:32 AM EDT - 5 months ago

Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners

Apr 9, 2026, 8:00 AM EDT - 5 months ago

Neuronetics Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 5 months ago

Neuronetics Proxy statement: Proxy filing

2026-04-06T20:41:11.000Z - 5 months ago

Neuronetics backs FY26 revenue view $160M-$166M, consensus $162.47M

2026-04-06T20:36:05.000Z - 5 months ago

Neuronetics CFO Steven Pfanstiel to depart

2026-04-06T20:35:09.000Z - 5 months ago

Neuronetics backs Q1 revenue view $33M-$35M, consensus $34.18M

2026-04-06T20:11:09.000Z - 5 months ago

Neuronetics’ largest independent shareholder urges review of alternatives

Apr 6, 2026, 4:05 PM EDT - 5 months ago

Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business

2026-03-19T10:45:58.000Z - 6 months ago

Neuronetics price target lowered to $3 from $7 at Canaccord

CMPS

2026-03-17T21:00:32.000Z - 6 months ago

Neuronetics files to sell 20.74M shares of common stock for holders

Mar 17, 2026, 8:30 AM EDT - 6 months ago

Neuronetics Earnings Call Transcript: Q4 2025

Mar 17, 2026, 8:30 AM EDT - 6 months ago

Neuronetics Annual report: Q4 2025

Mar 17, 2026, 8:30 AM EDT - 6 months ago

Neuronetics Earnings release: Q4 2025

Mar 17, 2026, 8:30 AM EDT - 6 months ago

Neuronetics Slides: Q4 2025

Mar 17, 2026, 8:00 AM EDT - 6 months ago

Neuronetics Registration statement: Registration Filing

2026-03-17T11:55:48.000Z - 6 months ago

Neuronetics reports Q4 EPS (10c) vs. (34c) last year

2026-03-17T11:55:39.000Z - 6 months ago

Neuronetics sees Q1 revenue $33M-$35M, consensus $37.22M

2026-03-17T11:55:14.000Z - 6 months ago

Neuronetics sees FY26 revenue $160M-$166M, consensus $164.15M

2026-03-17T11:50:30.000Z - 6 months ago

Neuronetics appoints Dan Reuvers as President and CEO

Mar 17, 2026, 7:50 AM EDT - 6 months ago

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mar 17, 2026, 7:45 AM EDT - 6 months ago

Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

2026-02-10T21:45:58.000Z - 7 months ago

Neuronetics reports preliminary Q4 revenue $41.8M, consensus $40.66M

Feb 10, 2026, 4:34 PM EST - 7 months ago

Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

Nov 20, 2025, 8:30 AM EST - 10 months ago

Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 12, 2025, 10:33 AM EST - 10 months ago

TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression

Nov 4, 2025, 8:30 AM EST - 10 months ago

Neuronetics Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Neuronetics Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Neuronetics Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Neuronetics Slides: Q3 2025

Nov 4, 2025, 7:05 AM EST - 10 months ago

Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan

Oct 30, 2025, 8:32 AM EDT - 10 months ago

Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence

Oct 21, 2025, 8:30 AM EDT - 11 months ago

Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call

Sep 17, 2025, 8:32 AM EDT - 1 year ago

New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)

Aug 5, 2025, 8:30 AM EDT - 1 year ago

Neuronetics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 1 year ago

Neuronetics Earnings release: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 1 year ago

Neuronetics Quarterly report: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 1 year ago

Neuronetics Slides: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 30, 2025, 8:32 AM EDT - 1 year ago

NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents

Jul 15, 2025, 7:30 AM EDT - 1 year ago

Neuronetics Appoints New Chief Financial Officer

Jul 3, 2025, 8:00 AM EDT - 1 year ago

Neuronetics Registration statement: Registration Filing

Jun 10, 2025, 8:31 AM EDT - 1 year ago

Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial Program

Jun 2, 2025, 4:30 PM EDT - 1 year ago

Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

May 6, 2025, 8:30 AM EDT - 1 year ago

Neuronetics Earnings Call Transcript: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Neuronetics Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Neuronetics Earnings release: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Neuronetics Slides: Q1 2025

May 6, 2025, 7:10 AM EDT - 1 year ago

Neuronetics Reports First Quarter 2025 Financial and Operating Results

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Neuronetics Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Neuronetics Proxy statement: Proxy Filing

Mar 31, 2025, 8:31 AM EDT - 1 year ago

Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Neuronetics Proxy statement: Proxy Filing

Mar 4, 2025, 8:30 AM EST - 1 year ago

Neuronetics Earnings Call Transcript: Q4 2024

Mar 4, 2025, 8:30 AM EST - 1 year ago

Neuronetics Annual report: Q4 2024

Mar 4, 2025, 8:30 AM EST - 1 year ago

Neuronetics Earnings release: Q4 2024

Mar 4, 2025, 8:30 AM EST - 1 year ago

Neuronetics Slides: Q4 2024

Mar 4, 2025, 7:10 AM EST - 1 year ago

Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 7, 2025, 7:54 AM EST - 1 year ago

Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 4:23 PM EST - 1 year ago

Neuronetics Announces Launch of Underwritten Public Offering of Common Stock

Jan 29, 2025, 8:31 AM EST - 1 year ago

NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression

Dec 10, 2024, 10:00 AM EST - 1 year ago

Neuronetics and Greenbrook TMS Announce Closing of Transaction

Dec 4, 2024, 2:30 PM EST - 1 year ago

Neuronetics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 8:30 AM EST - 1 year ago

Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 6:45 PM EST - 1 year ago

CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results

Nov 12, 2024, 8:30 AM EST - 1 year ago

Neuronetics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Neuronetics Quarterly report: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Neuronetics Earnings release: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Neuronetics Slides: Q3 2024

Nov 12, 2024, 7:10 AM EST - 1 year ago

Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Neuronetics Proxy statement: Proxy Filing

Oct 29, 2024, 4:30 PM EDT - 1 year ago

Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call

Oct 14, 2024, 8:31 AM EDT - 1 year ago

NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Neuronetics Proxy statement: Proxy Filing

Oct 4, 2024, 8:33 AM EDT - 1 year ago

Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings

Oct 4, 2024, 8:00 AM EDT - 1 year ago

Neuronetics Proxy statement: Proxy Filing

Oct 4, 2024, 8:00 AM EDT - 1 year ago

Neuronetics Proxy statement: Proxy Filing

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Neuronetics Proxy statement: Proxy Filing

Sep 25, 2024, 8:31 AM EDT - 1 year ago

Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents

Sep 19, 2024, 8:31 AM EDT - 2 years ago

Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults

Sep 17, 2024, 8:00 AM EDT - 2 years ago

Neuronetics Proxy statement: Proxy Filing

Sep 16, 2024, 8:32 AM EDT - 2 years ago

NeuroStar® Releases Software Upgrades to Elevate Patient Care

Sep 3, 2024, 8:29 AM EDT - 2 years ago

NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Neuronetics Proxy statement: Proxy Filing

Aug 14, 2024, 3:00 PM EDT - 2 years ago

Neuronetics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Neuronetics Proxy statement: Proxy Filing

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Neuronetics Proxy statement: Proxy Filing

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Neuronetics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Neuronetics Quarterly report: Q2 2024

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Neuronetics Earnings release: Q2 2024

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Neuronetics Slides: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Neuronetics Proxy statement: Proxy Filing

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Neuronetics Proxy statement: Proxy Filing

Aug 12, 2024, 7:15 AM EDT - 2 years ago

Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge

Aug 12, 2024, 7:10 AM EDT - 2 years ago

Neuronetics Reports Record Second Quarter 2024 Financial and Operating Results

Aug 1, 2024, 8:29 AM EDT - 2 years ago

NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month

Jul 30, 2024, 8:30 AM EDT - 2 years ago

Neuronetics Announces the Closing of up to $90 Million Senior Secured Credit Facility with Perceptive Advisors

jacckkmm Sep. 18 at 1:17 PM

$STIM looking for a solid move today going into weekend…

0 · Reply

jacckkmm Sep. 17 at 7:58 PM

$STIM get to $3 :)

0 · Reply

Oscar_66 Sep. 17 at 5:06 PM

$STIM Looky looky!

0 · Reply

StellaLunaSun Sep. 17 at 2:29 PM

0 · Reply

LurkerLongtime Sep. 15 at 9:27 PM

0 · Reply

Ren_Stimpy Sep. 14 at 3:47 PM

$STIM sold half my share holdings for $3.20! Locked in some decent profits.

0 · Reply

MingChoo Sep. 13 at 2:03 PM

$STIM Upside potential

0 · Reply

Ren_Stimpy Sep. 11 at 7:55 PM

$STIM Sadly we probably won’t get any good PR till earnings. Short sellers will probably try and keep stock price low as they cover. Don’t see any big price movements in the near future.

1 · Reply

sam92 Sep. 11 at 3:14 PM

1 · Reply

Ren_Stimpy Sep. 11 at 11:51 AM

$STIM Finally got our analysis update!! Was starting to think it was never going to come..

0 · Reply

Quantumup Sep. 11 at 10:23 AM

BRiley🏁 $STIM and said -- We are initiating coverage of Neuronetics, Inc. (STIM) with a Buy rating and $5 price target (~70% upside), following the late-2024 Greenbrook acquisition and management reset in 2026. BWAY NPCE LIVN MDT BSX $CMPS $JNJ GHRS HELP ATAi - LLY DFTX Here's what else BRiley had to say in its initiation report: https://x.com/Quantumup1/status/2098356643331248365?s=20

0 · Reply

Trending__Now Sep. 9 at 6:20 PM

$STIM Took my profit. Nice run. Good luck.

1 · Reply

PreGigs Sep. 9 at 5:17 PM

$STIM Glad i've been buying the dips - making a killing here!

0 · Reply

lilgen Sep. 9 at 4:45 PM

$STIM running on no news

1 · Reply

Zackpedia Sep. 9 at 12:48 PM

$STIM You should’ve sold above 2.9

0 · Reply

speculator Sep. 9 at 11:40 AM

$STIM BTIG Reiterates Buy on Neuronetics, Maintains $6 Price Target

0 · Reply

Merlintrader Sep. 2 at 1:54 AM

Neuronetics ($STIM) Stock Hub 2026: Adjusted EBITDA Turned Positive — Can the Margin Hold Through the March 2027 Covenant? Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/neuronetics-stock-hub/

0 · Reply

Zackpedia Sep. 1 at 11:25 PM

$STIM Down to 2, you could’ve sold when I alerted.

1 · Reply

LurkerLongtime Sep. 1 at 6:02 PM

$CMPS $PSIL $STIM $OPTH

1 · Reply

PreGigs Aug. 31 at 3:46 PM

$STIM I think i'll add about 500 today :)

0 · Reply

Merlintrader Aug. 28 at 7:49 PM

$STIM Neuronetics stock hub: Q2 gross margin at 51.1%, adjusted EBITDA positive for the first time since the Greenbrook deal, and five August filings that reshaped the register. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/neuronetics-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=neuronetics-stock-hub

0 · Reply

kn0_ox Aug. 28 at 7:42 PM

$STIM 5$

0 · Reply

Market Cap	220.97M
Revenue (ttm)	149.16M
Net Income (ttm)	-39.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-26.15%
Debt to Equity Ratio	2.84

Volume	623,482
Avg Vol	2,418,294
Day's Range	N/A - N/A
Shares Out	76.20M
Stochastic %K	44%
Beta	1.16
Analysts	Strong Sell
Price Target	$5.75